XBIO - Xenetic Biosciences, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Xenetic Biosciences reports results
• Xenetic Bio cut to Neutral at H.C. Wainwright on lack of catalysts
• Xenetic Biosciences announces reverse stock split of common stock
• Xenetic Biosciences reports Q1 results
• Xenetic Biosciences reports FY results
• Xenetic rises ~10% on upcoming Canadian patent for methods to improve cancer therapy
• Xenetic Biosciences GAAP EPS of -$0.06, revenue of $411.95M
• Xenetic Biosciences reports Q2 results
• Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
• Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement
• Xenetic inks clinical manufacturing contract with Catalent
• Xenetic Biosciences reports Q1 results
• Xenetic stock rises 10% on license deal for CLS Therapeutics' cancer drugs platform
• Xenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16M
• Xenetic Biosciences EPS misses by $0.01, beats on revenue
• Xenetic Bio secures new U.S. patent for CAR T platform technology
• Xenetic Biosciences EPS beats by $0.03, beats on revenue
• ERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losers
• Tyme Technologies, Xenetic Biosciences leads healthcare gainers; ATI Physical Therapy, Iterum Therapeutic among major losers
• Xenetic Biosciences rallies 45% on $12.5M private placement